Loading stock data…
APGE
$80.75-2.14 (-2.58%)
Market ClosedLast close May 1
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Apogee Therapeutics, Inc. in the Healthcare sector is trading at $80.75. The stock is currently 15% below its 52-week high of $95.31, remaining 30.6% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why APGE maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$80.75
Potential Upside
5%
Whystock Fair Value$84.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$118.31+46.5%
Range$82.00 – $160.00
Fundamentals
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indicat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.30%
Volume
Today's trading volume
472,564
Recent News
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ:APGE) ranks 6th on this list. Elite money managers are aggressively accumulating Apogee Therapeutics, Inc. (NASDAQ:APGE) stock, viewing it as the primary challenger to established blockbuster drugs in the immunology space. The firm recently released positive Phase […]
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data
Apogee Therapeutics recently completed a follow-on equity offering of approximately US$403,000,000, issuing 5,750,000 common shares at US$70.00 each after reporting positive 52-week Phase 2 APEX data for its lead atopic dermatitis drug candidate, zumilokibart. The Phase 2 results highlighted zumilokibart’s durable responses with less frequent 3- and 6-month maintenance dosing, while the fresh capital bolsters Apogee’s ability to fund later-stage clinical development. Next, we’ll examine how...
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
This biotech innovator in immunology reported a notable insider sale as its stock outperformed and drug development efforts continue.
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics jumps 20% as 52-week phase II Part A data show sustained efficacy of its AD candidate, zumilokibart, with durable responses and infrequent dosing boosting its promise.
How Apogee, Up 20%, Plans To Take On Rival Regeneron's Eczema Drug
Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, Dupixent.